AMBIEN CR Drug Patent Profile

When do Ambien Cr patents expire, and what generic alternatives are available?

Ambien Cr is a drug marketed by Cosette and is included in one NDA.

The generic ingredient in AMBIEN CR is zolpidem tartrate. There are thirty-three drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ambien Cr

A generic version of AMBIEN CR was approved as zolpidem tartrate by ACME LABS on April 23^rd, 2007.

Summary for AMBIEN CR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	23
Clinical Trials:	49
Patent Applications:	124
Drug Prices:	Drug price information for AMBIEN CR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AMBIEN CR
What excipients (inactive ingredients) are in AMBIEN CR?	AMBIEN CR excipients list
DailyMed Link:	AMBIEN CR at DailyMed

See drug prices for AMBIEN CR

See drug sales revenues for AMBIEN CR

Recent Clinical Trials for AMBIEN CR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institutes of Health (NIH)	Phase 2
University of Arizona	Phase 4
University of Virginia	Phase 4

See all AMBIEN CR clinical trials

Pharmacology for AMBIEN CR

Drug Class	gamma-Aminobutyric Acid A Receptor Positive Modulator
Mechanism of Action	GABA A Receptor Positive Modulators
Physiological Effect	Central Nervous System Depression

Paragraph IV (Patent) Challenges for AMBIEN CR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AMBIEN CR	Extended-release Tablets	zolpidem tartrate	6.25 mg	021774	1	2006-02-24
AMBIEN CR	Extended-release Tablets	zolpidem tartrate	12.5 mg	021774	1	2006-01-19

US Patents and Regulatory Information for AMBIEN CR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	AMBIEN CR	zolpidem tartrate	TABLET, EXTENDED RELEASE;ORAL	021774-002	Sep 2, 2005	AB	RX	Yes	No
Cosette	AMBIEN CR	zolpidem tartrate	TABLET, EXTENDED RELEASE;ORAL	021774-001	Sep 2, 2005	AB	RX	Yes	Yes

International Patents for AMBIEN CR

See the table below for patents covering AMBIEN CR around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	143146	CONTROLLED-RELEASE DOSAGE FORMS COMPRISING ZOLPIDEM OR A SALT THEREOF
Taiwan	565448
Greece	74701
European Patent Office	1005863
Japan	S5798283	IMIDAZOPYRIDINE DERIVATIVE
Australia	7668781

Supplementary Protection Certificates for AMBIEN CR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2236132	92636	Luxembourg		PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
2236132	CA 2015 00004	Denmark		PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
2236132	300714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718
2236132	C300714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
2236132	122015000006	Germany		PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718

AMBIEN CR (zolpidem) Market Dynamics and Financial Trajectory

Last updated: April 26, 2026

What is AMBIEN CR’s commercial positioning?

AMBIEN CR is the extended-release formulation of zolpidem tartrate, an oral hypnotic used for insomnia. In market terms, AMBIEN CR sits in the “sleep” category dominated by Schedule IV controlled substances and is heavily exposed to (1) payer scrutiny over utilization and safety, (2) prescriber behavior and switching within zolpidem/alternative hypnotic classes, and (3) generic erosion dynamics.

Key product attributes that shape demand and pricing:

• Product type: extended-release zolpidem tartrate (brand name “Ambien CR”)
• Category drivers: short-term insomnia treatment pattern; chronic use typically faces tighter prescribing guardrails
• Regulatory and safety overlay: controlled-substance status and well-publicized CNS adverse events shape prescriber and payer controls (step edits, prior authorization in some formularies)

How does the market structure affect sales velocity and pricing?

1) Generic substitution is the dominant market dynamic

For most legacy branded hypnotics, the long-run trajectory is governed by patent and exclusivity expiry, followed by generic penetration and price compression. AMBIEN CR’s financial trajectory is therefore structurally similar to other mature branded sleep medicines: once generics take share, net price falls faster than volume can compensate.

2) Payers manage utilization with formulary controls

Across insomnia drug classes, payer controls tend to target:

• Appropriate-use editing (step therapy or prior authorization in some plans)
• Quantity and duration limits
• Age and safety-related restrictions (sleep meds are typically subject to tighter controls for older adults)

These controls directly affect scripts that might otherwise flow to AMBIEN CR versus alternatives that are preferred at lower net price.

3) Prescriber behavior favors lower-cost equivalents

Extended-release zolpidem competes in a narrow therapeutic segment where switching is easy at the pharmacy level. When a payer prefers generic zolpidem or an alternative hypnotic, branded AMBIEN CR faces both:

• Formulary placement disadvantages
• Patient continuity loss (scripts rewritten after renewal cycles)

What is the likely financial trajectory profile for AMBIEN CR?

Without company-reported segment disclosures dedicated to AMBIEN CR alone, the best-supported trajectory profile for a mature branded controlled-substance insomnia product is:

1. Early/mid lifecycle: brand premium pricing with moderate-to-strong prescription momentum
2. Exclusivity window: share erosion begins and price pressure intensifies
3. Post-generic penetration: net revenue declines are driven by:
   • Lower average net price
   • Lower branded share
   • Continued demand only from patients who cannot switch or prefer brand for non-clinical reasons (declining over time)

This profile is consistent with market mechanics for branded CNS products after generics enter.

What policy and compliance factors can constrain growth?

Controlled-substance scheduling

Zolpidem is regulated as a controlled substance (Schedule IV). That changes prescribing workflows and oversight intensity versus non-controlled hypnotics. It also creates friction for substitution programs where payers and pharmacies tightly manage controlled-substance inventory and monitoring.

Safety and labeling pressure

CNS hypnotics face persistent scrutiny around:

• Next-day impairment risk
• Falls and cognitive adverse events
• Misuse and dependence potential

Even when clinical efficacy remains consistent, these issues increase the probability of:

• More conservative prescribing
• Formulary restrictions
• Increased use of lower-cost alternatives after safety communications

How does the competitive set shape AMBIEN CR’s unit economics?

AMBIEN CR competes primarily across:

• Direct zolpidem alternatives: immediate-release zolpidem branded or generic equivalents; payer preference varies by plan design
• Other hypnotic classes: non-benzodiazepine “Z-drugs” and other insomnia pharmacotherapies (some have different payer incentives)

In sleep therapeutics, competitive advantage is often expressed less as pharmacodynamic superiority and more as:

• Net price and formulary status
• Coverage durability
• Switching friction

Once generics dominate, AMBIEN CR’s “premium” advantage narrows to non-cost drivers.

What can be inferred about AMBIEN CR’s performance metrics?

While this report cannot attach verified dollar sales figures to AMBIEN CR specifically without product-level financial disclosures, the market mechanics imply the following performance directionality:

Expected near- to mid-term trajectory

• Branded units: declining trend after broad generic penetration
• Net revenue: declining faster than units due to net price compression and increased rebates/discounting (where applicable)
• Manufacturing and distribution: continuing volume for generic equivalents (brand brand-share declines)

Key financial sensitivity

AMBIEN CR’s financial trajectory is most sensitive to:

• Rate of generic share takeover within extended-release zolpidem
• Payer formulary position relative to preferred hypnotics
• State-level and plan-level controlled-substance policies

What are the practical market levers for R&D and investment decisions?

1) Expect demand to be “coverage-led,” not “innovation-led”

In mature insomnia markets with generic competition, the highest-yield actions typically relate to coverage strategies rather than incremental clinical differentiation.

2) Plan for swapability

Extended-release hypnotics are often interchangeable at the therapeutic class level, so branded offerings face immediate share loss if a preferred generic exists.

3) Treat safety communications as commercial events

Safety-driven restrictions can accelerate share shift away from branded controlled substances to preferred options, even when overall category demand remains stable.

---

Key Takeaways

• AMBIEN CR is a mature branded controlled-substance insomnia product whose long-run financial path is dominated by generic substitution, payer controls, and prescriber switching.
• Market dynamics point to sustained branded share erosion and net price compression, producing a trajectory of declining branded revenue over time.
• Commercial outcomes are highly sensitive to formulary placement and utilization management more than to incremental differentiation.

---

FAQs

1. Is AMBIEN CR exposed to generic erosion?
   Yes. As with other mature branded zolpidem products, generic entry is the primary driver of long-term branded revenue decline.

2. What drives payer decisions for insomnia drugs like AMBIEN CR?
   Plan design typically emphasizes utilization management (prior authorization or quantity/duration limits) and safety guardrails.

3. Does controlled-substance status affect commercial dynamics?
   Yes. Schedule IV status increases oversight and affects prescribing and dispensing workflows relative to non-controlled products.

4. How does AMBIEN CR typically compete in the sleep category?
   It competes through net price and formulary preference versus generic zolpidem and alternative hypnotic classes.

5. What is the most important variable for forecasting AMBIEN CR branded revenue?
   The speed and breadth of generic share takeover within extended-release zolpidem and the persistence of branded formulary restrictions.

---

References

[1] FDA. “Zolpidem Tartrate.” Drug Label / information pages (accessed via FDA drug listings).
[2] FDA. “Ambien CR (zolpidem tartrate) Prescribing Information.” FDA label repository.
[3] DEA. “Drug Scheduling: Controlled Substances.” U.S. Drug Enforcement Administration schedules and controlled substance information.